As the life sciences industry continues to evolve rapidly, clinical research organizations (CROs) and trial sites are facing new challenges and opportunities in 2024. This webinar is designed to provide industry leaders with a deep dive into the most critical trends impacting clinical trials and the strategies needed to navigate these effectively.
Tom Gregson is the Vice President of Business Development at Myonex, a clinical trial supply company. With a decade of experience, he spearheads global sales of all clinical supply services, serving pharmaceutical and biotech companies, as well as CROs. Tom plays a crucial role in managing Myonex’s largest global clients and driving strategic growth.
One of the biggest focuses of 2024 is on the patient – from recruitment to retention, these elements of your trial quickly become key success factors. Sourcing strategies and site dependency can drastically impact your first patient in timelines and the retention efforts throughout the trial duration.
Managing multiple vendors and the dependency on them to cross-communicate and deliver on time requires you to be in control and accountable – even for things out of your control. Learn how to reduce that dependency and complexity.
A trend that’s only on the rise, what strategies can you deploy to ensure these trial designs don’t delay your trial or complicate your overall trial management.
Hybrid approaches to clinical trials only further push the focus around patient-centric trials. DCT and DTP approaches allow for further engagements from trial participants and offer convenience, potentially increasing patient recruitment and retention.
Another critical aspect of your clinical trial – we’ll discuss the strategies available to accelerate your ability to meet first patient in and ensure the rest of your trial stays on time
We’ll address the essential aspect of Diversity, Equity, and Inclusion (DEI) in clinical trials considering FDAs guidance. The focus will be on the removal of financial barriers, such as insurance co-pays, to enhance study recruitment and increase retention. Inclusive trials not only fulfill ethical responsibilities but also contribute to more comprehensive and representative data, leading to better healthcare outcomes.
Key Takeaways
Better understand and identify the top industry trends being seen as it relates to drug supplies
How to strategically meet and exceed
these trends
Shorten timelines, reduce costs, and ensure your trial is faster, more flexible, and reliable